Concepedia

Toshikazu Moriwaki

TM

Statistics

Publications

48

Citations

4.2K

H-Index

28

Active since

2003

Affiliations

University of Tsukuba(Current)

National Cancer Center Hospital East

Shikoku Cancer Center

Aichi Cancer Center

Chiba Cancer Center

Toshikazu Moriwaki is an author at University of Tsukuba specializing in medicine, oncology, and chemotherapy.

ORCID

Publications per year

2003–2023

48

Publications

48

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima, Manish A. Shah, Kei Muro et al. · Journal of Clinical Oncology · 2020 · 1.2K citations

, , +17

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 559 citations

, , +10

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki et al. · The Lancet Oncology · 2012 · 325 citations

, , +10

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

, , +8

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Takashi Kojima, Kei Muro, Éric François et al. · Journal of Clinical Oncology · 2019 · 207 citations

, , +12

1–5 of 48